511 related articles for article (PubMed ID: 16033483)
1. [Vaccination therapy of melanoma].
Schuler-Thurner B; Schuler G
J Dtsch Dermatol Ges; 2005 Aug; 3(8):630-45. PubMed ID: 16033483
[No Abstract] [Full Text] [Related]
2. [New aspects of immunotherapy of malignant melanoma].
Enk A
Praxis (Bern 1994); 2001 Mar; 90(10):403-6. PubMed ID: 11305186
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell vaccination as a treatment modality for melanoma.
Eubel J; Enk AH
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1631-42. PubMed ID: 19895246
[TBL] [Abstract][Full Text] [Related]
4. [To outwit melanoma with its own tricks].
Bischoff A
MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
[No Abstract] [Full Text] [Related]
5. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma.
Gordon LK; Ribas A; Nusinowitz S; Butterfield LH; Glaspy JA; Economou JS; Straatsma BR
Control Clin Trials; 2004 Aug; 25(4):400-7. PubMed ID: 15296814
[TBL] [Abstract][Full Text] [Related]
6. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
Sondak VK; Sosman JA
Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
[TBL] [Abstract][Full Text] [Related]
7. DC therapy for metastatic melanoma.
Ingram SB; O'Rourke MG
Cytotherapy; 2004; 6(2):148-53. PubMed ID: 15203991
[No Abstract] [Full Text] [Related]
8. Melanoma and immunotherapy.
Eggermont AM; Schadendorf D
Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy of melanoma].
Dummer R; Nestle FO; Burg G
Dtsch Med Wochenschr; 2000 Oct; 125(41):1240-2. PubMed ID: 11076264
[No Abstract] [Full Text] [Related]
10. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
11. New treatments for melanoma.
Demierre MF; Allten S; Brown R
Dermatol Nurs; 2005 Aug; 17(4):287-95. PubMed ID: 16206683
[No Abstract] [Full Text] [Related]
12. Melanoma antigens and targets for vaccination.
Kang N; Truman H; Sanders R; Kupsch J
Br J Hosp Med; 1997 Sep 17-30; 58(6):282-6. PubMed ID: 9488805
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters.
Nakai N; Hartmann G; Kishimoto S; Katoh N
Pigment Cell Melanoma Res; 2010 Oct; 23(5):607-19. PubMed ID: 20579307
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
15. [Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients].
Baldueva IA; Novik AV; Moiseenko VM; Nekhaeva TL; Danilova AB; Danilov AO; Protsenko SA; Petrova TIu; Uleĭskaia GI; Shchekina LA; Semenova AI; Mikhaĭlichenko TD; Teletaeva GM; Zhabina AS; Volkov NV; Komarov IuI
Vopr Onkol; 2012; 58(2):212-21. PubMed ID: 22774527
[TBL] [Abstract][Full Text] [Related]
16. [Vaccinal cell therapy in melanoma].
Quillien V; Lesimple T; Toujas L
Bull Cancer; 2003; 90(8-9):722-33. PubMed ID: 14609762
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell immunotherapy for stage IV melanoma.
O'Rourke MG; Johnson MK; Lanagan CM; See JL; O'Connor LE; Slater GJ; Thomas D; Lopez JA; Martinez NR; Ellem KA; Schmidt CW
Melanoma Res; 2007 Oct; 17(5):316-22. PubMed ID: 17885587
[TBL] [Abstract][Full Text] [Related]
18. Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial.
Ribas A; Weber JS; Chmielowski B; Comin-Anduix B; Lu D; Douek M; Ragavendra N; Raman S; Seja E; Rosario D; Miles S; Diamond DC; Qiu Z; Obrocea M; Bot A
Clin Cancer Res; 2011 May; 17(9):2987-96. PubMed ID: 21385924
[TBL] [Abstract][Full Text] [Related]
19. Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal.
Rosenthal R; Viehl CT; Guller U; Weber WP; Adamina M; Spagnoli GC; Heberer M; Zuber M
J Am Coll Surg; 2008 Jul; 207(1):95-105. PubMed ID: 18589368
[No Abstract] [Full Text] [Related]
20. Vaccination: role in metastatic melanoma.
Pilla L; Valenti R; Marrari A; Patuzzo R; Santinami M; Parmiani G; Rivoltini L
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1305-18. PubMed ID: 16925496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
